Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | RAF1 | P04049 | 8/20 | 0.55 |
| ▸ | CSF1R | P07333 | 4/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.54 |
| ▸ | LYN | P07948 | 3/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 2/20 | 0.50 |
| ▸ | LCK | P06239 | 2/20 | 0.50 |
| ▸ | HCK | P08631 | 2/20 | 0.50 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | TEK | Q02763 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4256187 | 0.91 | BRAF (0.63) | BRAFRAF1CSF1RNTRK1LYN | |
| SCHEMBL4257833 | 0.89 | CSF1R (0.66) | BRAFRAF1CSF1RNTRK1NTRK2 | |
| SCHEMBL4253236 | 0.89 | BRAF (0.54) | BRAFRAF1CSF1RNTRK1NTRK2 | |
| SCHEMBL4829508 | 0.85 | CSF1R (0.68) | BRAFRAF1CSF1R | |
| SCHEMBL4250376 | 0.84 | CSF1R (0.67) | BRAFRAF1CSF1RNTRK1NTRK2 | |
| SCHEMBL4258210 | 0.80 | RAF1 (0.60) | BRAFRAF1CSF1RNTRK1LYN | |
| SCHEMBL1358527 | 0.79 | HDAC3 (0.58) | BRAFCSF1RLCKSRCKDR | |
| SCHEMBL14069589 | 0.79 | BRAF (0.54) | BRAFRAF1CSF1RLYNINSR | |
| SCHEMBL4789368 | 0.79 | BRAF (0.60) | BRAFRAF1CSF1RNTRK1NTRK2 | |
| SCHEMBL4257827 | 0.78 | CSF1R (0.65) | BRAFRAF1CSF1RLYNINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | claimed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
| EP-1841431-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081172-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | BRAF 8/4885RAF1 10/4885CSF1R 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.